FMP
Valbiotis SA
ALVAL.PA
EURONEXT
Valbiotis SA engages in the research and development of health nutrition products to prevent and combat metabolic and cardiovascular diseases. The company develops TOTUM-63 that is in Phase II/III clinical trials for the treatment of type 2 diabetes; TOTUM-070, which is in Phase II clinical trials to treat hypercholesterolemia; and TOTUM-854 that is in Phase II/III clinical trials for arterial hypertension. It also develops TOTUM-448 for the treatment of patient with non-alcoholic fatty liver disease. It has a strategic partnership with Nestlé Health Science. Valbiotis SA was incorporated in 2014 and is headquartered in Périgny, France.
3.87 EUR
-0.02 (-0.517%)
About
ceo
Mr. Sebastien Peltier HDR, Ph.D.
sector
Healthcare
industry
Biotechnology
website
https://www.valbiotis.com
exchange
EURONEXT
Description
Valbiotis SA engages in the research and development of health nutrition products to prevent and combat metabolic and cardiovascular diseases. The company develops TOTUM-63 that is in Phase II/III clinical trials for the treatment of type 2 diabetes; TOTUM-070, which is in Phase II clinical trials to treat hypercholesterolemia; and TOTUM-854 that is in Phase II/III clinical trials for arterial hypertension. It also develops TOTUM-448 for the treatment of patient with non-alcoholic fatty liver disease. It has a strategic partnership with Nestlé Health Science. Valbiotis SA was incorporated in 2014 and is headquartered in Périgny, France.
CIK
N/A
ISIN
FR0013254851
CUSIP
F966A0104
Address
rue Paul Vatine
Phone
33 5 46 28 62 58
Country
FR
Employee
48
IPO Date
Jun 7, 2017
Key Executives
